Apellis Pharmaceuticals
Waltham, Massachusetts, United States · Biopharma, Biotechnology, Healthcare
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face.
Key facts
- Headquarters
- Waltham, Massachusetts, United States
- Employees
- 710
- Industries
- Biopharma, Biotechnology, Healthcare
- Website
- apellis.com
- Company page
Recent activity at Apellis Pharmaceuticals
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On April 28, 2026, Apellis Pharmaceuticals, Inc. approved an amendment and restatement of its Executive Separation Benefits and Retention Plan as a part of the Merger Agreement with Biogen Inc. and Aspen Purchaser Sub, Inc. This plan will accelerate and vest certain unvested rights of participants, including named executive officers, in the event of termination under specified conditions, which are crucial given the impending merger. The amendment also modifies the definition of 'Good Reason' for C-Level Officers, providing additional protection against employment termination due to the company's subsidiary status post-merger. The amendments are effective contingent upon the Closing Date as defined in the Merger Agreement.
- : SEC 8-K (5.02): On March 30, 2026, Apellis Pharmaceuticals, Inc.'s compensation committee approved the Excise Tax Gross-Up Plan, allowing 'disqualified individuals' including the company's named executive officers to receive gross-up payments if their compensation related to an upcoming merger becomes subject to excise tax. These payments aim to place participants in the same after-tax position they would be in if the tax did not apply, with a total cap of $25 million on gross-up payments across all participants. The plan is effective upon the consummation of the merger with Biogen, which was announced through a joint press release on March 31, 2026, indicating that significant changes are underway in corporate governance relating to the merger.
- : SEC 8-K (5.02): On February 27, 2026, Apellis Pharmaceuticals, Inc. elected Mikael Dolsten, M.D., Ph.D. to its Board of Directors as a Class I director, effective March 1, 2026, with a term lasting until the 2027 Annual Meeting of Stockholders. Dr. Dolsten has been classified as 'independent' under Nasdaq rules and will receive compensation in line with other non-employee directors. As part of his appointment, he was granted options to purchase company stock and restricted stock units, both valued at $300,000, with specific vesting conditions including acceleration in the event of a change in control. There were no other arrangements or familial ties affecting his election, ensuring a straightforward appointment process.
- : SEC 8-K (2.02): On January 12, 2026, Apellis Pharmaceuticals, Inc. announced its preliminary unaudited total U.S. net product revenues and net product revenues for SYFOVRE and EMPAVELI for the fourth quarter and full year ending December 31, 2025. The announcement includes the Company’s cash and cash equivalents as of December 31, 2025. These figures are preliminary and subject to change as they are unaudited and represent management’s estimates pending the completion of financial closing procedures. This disclosure is significant for investors as it provides key insights into the Company’s financial health and performance during the specified period.
- : Apellis Pharmaceuticals announces the approval of SYFOVRE® for geographic atrophy treatment in Australia.
- : Apellis Pharmaceuticals, Inc.
- : Apellis Pharmaceuticals, Inc.
- : Apellis Pharmaceuticals, Inc.
- : Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2017 | Venture | $20.0M |
| Feb 2016 | Venture | $47.1M |
| Jan 2016 | Venture | $32.1M |
| Jun 2015 | Venture | $17.7M |
Leadership
- Maha Katabi, Director
- Robert Adelman, Director
- Bihua Chen, Director
- Stephanie O'Brien, Director
- Gerald Chan, Director
- Alec Machiels, Director
- A. Dunlop, Director
- Cedric Francois, Executive Officer, Director
- Robert Adelman, Director
- Bihua Chen, Director
- Stephanie O'Brien, Director
- Gerald Chan, Director
Verified email and direct lines for Apellis Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Apellis Pharmaceuticals files 5 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Apellis Pharmaceuticals in the news
- Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals - Pharmaceutical Executive (Apr 01, 2026)
- Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times (May 18, 2026)
- Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy - BioSpace (Mar 31, 2026)
- Biogen to acquire immunology biotech Apellis for $5.6 billion - STAT (Mar 31, 2026)
- Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - Biogen (Mar 31, 2026)
- Philip Ferrone, MD, to join Apellis Pharmaceuticals as Chief Medical Retina Advisor - Ophthalmology Times (Jul 08, 2026)
- Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire (Mar 31, 2026)
- Biogen Completes Acquisition of Apellis Pharmaceuticals - Biogen (May 14, 2026)
Companies similar to Apellis Pharmaceuticals
- Madrigal Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Crinetics Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Aquestive Therapeutics, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Os Therapies · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Apellis Pharmaceuticals: questions and answers
What does Apellis Pharmaceuticals do?
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face.
Where is Apellis Pharmaceuticals headquartered?
Apellis Pharmaceuticals is headquartered in Waltham, Massachusetts, United States.
How many employees does Apellis Pharmaceuticals have?
Apellis Pharmaceuticals has about 710 employees.
Has Apellis Pharmaceuticals raised funding?
Yes. Fundz has recorded 4 funding events for Apellis Pharmaceuticals. The most recent, $20.0M, was in Aug 2017.
What is the latest news on Apellis Pharmaceuticals?
On May 14, 2026, SEC 8-K (5.02):
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy